Navigation Links
Techne Corporation Releases Unaudited Second Quarter And Six Month Fiscal Year 2013 Results
Date:2/5/2013

rter of fiscal 2013.  The amount of the retroactive credit is approximately $975,000.

The Company's investment in ChemoCentryx, Inc. (CCXI) is included in short-term available for sale investments at December 31, 2012 at a fair-value of $69.1 million.  The Company's unrealized gain of $39.6 million on the investment, net of a deferred tax liability of $14.2 million, was included in accumulated other comprehensive income at December 31, 2012.

The Company did not repurchase any shares of its common stock during the quarter or six-month periods ended December 31, 2012.  Approximately $127 million remains available at December 31, 2012 for the repurchase and retirement of shares under the currently open authorization.

Forward Looking Statements:

Our press releases may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Such statements, including the expected effective tax rate, involve risks and uncertainties that may affect the actual results of operations. The following important factors, among others, have affected and, in the future, could affect the Company's actual results: the introduction and acceptance of new biotechnology and hematology products, the levels and particular directions of research by the Company's customers, the impact of the growing number of producers of biotechnology research products and related price competition, general economic conditions, the impact of currency exchange rate fluctuations, and the costs and results of research and product development efforts of the Company and of companies in which the Company has invested or with which it has formed strategic relationships.

For additional information concerning such factors, see the section titled "Risk Factors" in the Company's annual report on Form 10-K and quarterly reports on Form 10-Q as filed with the Securities and Exchange Commission. We undertake no obligation to update or revise
'/>"/>

SOURCE Techne Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Techne Corporation Releases Unaudited Fourth Quarter And Fiscal Year 2012 Results
2. Techne Corporation Releases Unaudited Third Quarter and Nine Month Fiscal Year 2012 Results
3. Luminex Corporation Reports Fourth Quarter And Full Year 2012 Results
4. NewLink Genetics Corporation Announces Exercise of Underwriters Option and Closing of Public Offering of Common Stock
5. MGC Diagnostics Corporation Appoints Wesley W. Winnekins as Executive Vice President, Finance and Corporate Development; Winnekins will also serve as Chief Financial Officer
6. Luminex Corporation To Present At Leerink Swann Global Healthcare Conference
7. NewLink Genetics Corporation Announces Pricing of Public Offering of Common Stock
8. NewLink Genetics Corporation Announces Proposed Public Offering of Common Stock
9. CVS Caremark Corporation To Hold Fourth Quarter 2012 Conference Call
10. The law firms of Bernstein Litowitz Berger & Grossmann LLP and Labaton Sucharow LLP announce pendency of class action in In re Schering-Plough Corporation / ENHANCE Securities Litigation
11. MGC Diagnostics Corporation Reports Fourth Quarter and Fiscal Year 2012 Operating Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2014)... Investor-Edge has initiated coverage on the following equities: ... Company (NYSE: LLY ), Nektar Therapeutics (NASDAQ: ... Novartis AG (NYSE: NVS ). Free research on ... . On Friday, December 12, 2014, the NASDAQ Composite ... lost 1.79%, to finish the day at 17,280.83, and the ...
(Date:12/15/2014)... and BOSTON , December 15, 2014 ... structure-guided drug discovery and development company, is pleased to ... the United States relating to its ... in the US significantly strengthens the global patent estate ... markets. The suite of patents recently granted ...
(Date:12/13/2014)... HUNTSVILLE, Ala. , Dec. 12, 2014 /PRNewswire-USNewswire/ ... has purchased the HiSeq X Ten sequencing system ... will enable HudsonAlpha to produce and analyze genomic ... purchase stems from the Institute,s commitment to research ... The HiSeq X Ten provides unprecedented capacity, ...
Breaking Medicine Technology:Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 2Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 3Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 4Analysts View on Pharma Equities - Zogenix, Eli Lilly, Nektar Therapeutics, Sanofi, and Novartis 5Heptares Extends Global Patent Protection for GPCR-Focused Drug Discovery Platform With Grant of Core Patents in the United States 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 2HudsonAlpha announces purchase of Illumina HiSeq X Ten sequencing system 3
... Clot Retention and Decreases Residual Clot Volume , ... Cardiovascular LLC announced today that data presented at the ... Cardiothoracic Surgery show that administration of a heparin bolus ... vein harvest (EVH) was associated with improved acute saphenous ...
... , --First of 2 data sets to be released-- ... from two randomized, active-controlled clinical trials in patients with blepharospasm ... upper limb spasticity trial -- were presented at the Movement ... The studies were sponsored by Merz Pharmaceuticals, which plans to ...
Cached Medicine Technology:Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients 2Heparin Use Prior to Endoscopic Vein Harvest Improves Graft Patency in Off-Pump Coronary Artery Bypass Patients 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 2Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 3Merz Pharmaceuticals Announces Results of Clinical Trials with NT-201(Botulinum neurotoxin type A free from complexing proteins) at Annual Movement Disorders Society Meeting 4
(Date:12/17/2014)... Mozes HealthDay Reporter , TUESDAY, ... infectious diseases, one worrisome phenomenon is when an illness that ... -- known as zoonosis -- is not uncommon and keeps ... an animal-borne disease might make inroads into the human population. ... -- and the culprits in this case were guinea pigs. ...
(Date:12/17/2014)... HealthDay Reporter , TUESDAY, Dec. 16, ... improve overall health, but a growing body of evidence shows ... review finds. In fact, the benefits were similar to ... researcher Paula Chu, a doctoral candidate at Harvard University,s Health ... trials, found that people randomly assigned to take yoga classes ...
(Date:12/15/2014)... Main Street Dental Team ( http://www.MainStreetDentalTeam.com ... on a new study providing evidence on the impact ... of children. , Sufficient enough evidence already exists showing ... or juice drinks, with the onset of tooth decay. ... drinks listed as 100% fruit juice, meaning it is ...
(Date:12/15/2014)... By Steven Reinberg ... -- A large, new study should reassure the millions of ... the risk for breast cancer. "There is no association ... Tamimi, an associate professor of medicine at Harvard Medical School. ... for concern, and there is no protective effect either." ...
(Date:12/15/2014)... OR (PRWEB) December 15, 2014 ... seeks to bring attention to restrictive state laws ... position paper on this important area of public ... Laws Can Compromise the Integrity of Independent Review, ... and access of independent peer review determinations can ...
Breaking Medicine News(10 mins):Health News:Guinea Pigs Can Be Source of Serious Strep Infection 2Health News:Guinea Pigs Can Be Source of Serious Strep Infection 3Health News:Yoga May Cut Heart Disease Risk Factors 2Health News:Yoga May Cut Heart Disease Risk Factors 3Health News:Main Street Dental Team, Unionville’s Most Innovative Dental Clinic, Comments on New Study Relating Pure Fruit Juice to Poor Oral Hygiene 2Health News: No Link Between Migraine, Breast Cancer Risk, Study Says 2Health News:NAIRO Calls for Higher Quality Independent Peer Review By Ending Restrictive State Laws 2
... a chlorine gas disaster in a South Carolina town gives ... how to prepare emergency response systems for an accidental or ... now available in the January 2009 issue of the ... one of the largest community exposures to chlorine gas since ...
... of chronic abdominal pain of luminal etiology is a ... The exact localization of lesion to either small or ... In tropical countries, where most of the population is ... which screens small and large bowel lesions simultaneously at ...
... 29 Stereotaxis, Inc.,(Nasdaq: STXS ) today ... existing institutional investors to raise gross proceeds of $20,million ... two separate,concurrent transactions. A portion of the warrants sold ... these warrants would provide an additional,approximately $10 million in ...
... study finds , , MONDAY, Dec. 29 (HealthDay News) -- ... have sex as teens who don,t make such promises -- ... disease or pregnancy, a new study finds. , "Previous studies ... than non-pledgers," said study author Janet E. Rosenbaum, a post ...
... 5k Walks Drive Home Importance of Awareness and Education ... an effort to raise money for The Kidney TRUST(TM) ... of chronic kidney disease (CKD) -- DaVita Inc., the ... that the 3rd annual "Kidney Awareness Time(TM)" Walk-a-thon (The ...
... Free Company Plans New Products and Expanded Services in 2009 ... ... Vista, LLC has reported its seventh consecutive year of revenue growth ... and strong demand for media relations and marketing services provided by ...
Cached Medicine News:Health News:New study examines effects of Graniteville, S.C., chlorine gas disaster 2Health News:New study examines effects of Graniteville, S.C., chlorine gas disaster 3Health News:A new screening test for chronic abdominal pain 2Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 2Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 3Health News:Stereotaxis to Raise $20 Million in Registered Direct Offering of Common Stock and Warrants 4Health News:Many Teens Don't Keep Virginity Pledges 2Health News:Many Teens Don't Keep Virginity Pledges 3Health News:Thousands of DaVita Teammates Raise Over $100,000 for CKD Programs 2Health News:Thousands of DaVita Teammates Raise Over $100,000 for CKD Programs 3Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 2Health News:Fisher Vista, LLC Reports Seventh Consecutive Year of Revenue Growth and Profitability 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: